2019 Future of Trigeminal Neuralgia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Trigeminal Neuralgia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Trigeminal Neuralgia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Trigeminal Neuralgia pipeline companies from advancing their products into Phase 3 or Phase 4.
Trigeminal Neuralgia Report Description-
The 2019 pipeline study on Trigeminal Neuralgia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Trigeminal Neuralgia pipeline compounds.
The Trigeminal Neuralgia pipeline guide presents information on all active drugs currently being developed for Trigeminal Neuralgia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Trigeminal Neuralgia pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Trigeminal Neuralgia drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Trigeminal Neuralgia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Trigeminal Neuralgia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Trigeminal Neuralgia pipeline report includes-
Trigeminal Neuralgia Report Description-
The 2019 pipeline study on Trigeminal Neuralgia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Trigeminal Neuralgia pipeline compounds.
The Trigeminal Neuralgia pipeline guide presents information on all active drugs currently being developed for Trigeminal Neuralgia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Trigeminal Neuralgia pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Trigeminal Neuralgia drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Trigeminal Neuralgia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Trigeminal Neuralgia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Trigeminal Neuralgia pipeline report includes-
- An overview of Trigeminal Neuralgia disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Trigeminal Neuralgia pipeline
- Company wise list of Trigeminal Neuralgia pipeline
- Mechanism of Action wise Trigeminal Neuralgia pipeline
- For each pipeline candidate, the following details are provided
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Trigeminal Neuralgia pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Trigeminal Neuralgia pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Trigeminal Neuralgia pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL TRIGEMINAL NEURALGIA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Trigeminal Neuralgia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Trigeminal Neuralgia pipeline, H1- 2019
3.5 Mechanism of Action wise Trigeminal Neuralgia Pipeline Candidates
4 ALLODYNIC THERAPEUTICS, LLC TRIGEMINAL NEURALGIA PIPELINE DETAILS
4.1 Allodynic Therapeutics, LLC Business Profile
4.2 Allodynic Therapeutics, LLC Trigeminal Neuralgia Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 BIOGEN INC TRIGEMINAL NEURALGIA PIPELINE DETAILS
5.1 Biogen Inc Business Profile
5.2 Biogen Inc Trigeminal Neuralgia Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 CAPNIA, INC. TRIGEMINAL NEURALGIA PIPELINE DETAILS
6.1 Capnia, Inc. Business Profile
6.2 Capnia, Inc. Trigeminal Neuralgia Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 GRACE THERAPEUTICS LLC TRIGEMINAL NEURALGIA PIPELINE DETAILS
7.1 Grace Therapeutics LLC Business Profile
7.2 Grace Therapeutics LLC Trigeminal Neuralgia Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 INMED PHARMACEUTICALS INC TRIGEMINAL NEURALGIA PIPELINE DETAILS
8.1 InMed Pharmaceuticals Inc Business Profile
8.2 InMed Pharmaceuticals Inc Trigeminal Neuralgia Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 KPI THERAPEUTICS, INC. TRIGEMINAL NEURALGIA PIPELINE DETAILS
9.1 KPI Therapeutics, Inc. Business Profile
9.2 KPI Therapeutics, Inc. Trigeminal Neuralgia Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 MERZ PHARMA GMBH & CO. KGAA TRIGEMINAL NEURALGIA PIPELINE DETAILS
10.1 Merz Pharma GmbH & Co. KGaA Business Profile
10.2 Merz Pharma GmbH & Co. KGaA Trigeminal Neuralgia Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 OLIPASS CORPORATION TRIGEMINAL NEURALGIA PIPELINE DETAILS
11.1 OliPass Corporation Business Profile
11.2 OliPass Corporation Trigeminal Neuralgia Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 PIXARBIO CORPORATION TRIGEMINAL NEURALGIA PIPELINE DETAILS
12.1 PixarBio Corporation Business Profile
12.2 PixarBio Corporation Trigeminal Neuralgia Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. LATEST TRIGEMINAL NEURALGIA DRUG PIPELINE DEVELOPMENTS, 2019
14. APPENDIX
14.1 About Us
14.2 Sources and Methodology
14.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL TRIGEMINAL NEURALGIA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Trigeminal Neuralgia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Trigeminal Neuralgia pipeline, H1- 2019
3.5 Mechanism of Action wise Trigeminal Neuralgia Pipeline Candidates
4 ALLODYNIC THERAPEUTICS, LLC TRIGEMINAL NEURALGIA PIPELINE DETAILS
4.1 Allodynic Therapeutics, LLC Business Profile
4.2 Allodynic Therapeutics, LLC Trigeminal Neuralgia Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 BIOGEN INC TRIGEMINAL NEURALGIA PIPELINE DETAILS
5.1 Biogen Inc Business Profile
5.2 Biogen Inc Trigeminal Neuralgia Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 CAPNIA, INC. TRIGEMINAL NEURALGIA PIPELINE DETAILS
6.1 Capnia, Inc. Business Profile
6.2 Capnia, Inc. Trigeminal Neuralgia Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 GRACE THERAPEUTICS LLC TRIGEMINAL NEURALGIA PIPELINE DETAILS
7.1 Grace Therapeutics LLC Business Profile
7.2 Grace Therapeutics LLC Trigeminal Neuralgia Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 INMED PHARMACEUTICALS INC TRIGEMINAL NEURALGIA PIPELINE DETAILS
8.1 InMed Pharmaceuticals Inc Business Profile
8.2 InMed Pharmaceuticals Inc Trigeminal Neuralgia Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 KPI THERAPEUTICS, INC. TRIGEMINAL NEURALGIA PIPELINE DETAILS
9.1 KPI Therapeutics, Inc. Business Profile
9.2 KPI Therapeutics, Inc. Trigeminal Neuralgia Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 MERZ PHARMA GMBH & CO. KGAA TRIGEMINAL NEURALGIA PIPELINE DETAILS
10.1 Merz Pharma GmbH & Co. KGaA Business Profile
10.2 Merz Pharma GmbH & Co. KGaA Trigeminal Neuralgia Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 OLIPASS CORPORATION TRIGEMINAL NEURALGIA PIPELINE DETAILS
11.1 OliPass Corporation Business Profile
11.2 OliPass Corporation Trigeminal Neuralgia Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 PIXARBIO CORPORATION TRIGEMINAL NEURALGIA PIPELINE DETAILS
12.1 PixarBio Corporation Business Profile
12.2 PixarBio Corporation Trigeminal Neuralgia Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. LATEST TRIGEMINAL NEURALGIA DRUG PIPELINE DEVELOPMENTS, 2019
14. APPENDIX
14.1 About Us
14.2 Sources and Methodology
14.3 Contact Information
